US20090298062A1 - Method for determination of the length of the g-tail sequence and kit for the method - Google Patents

Method for determination of the length of the g-tail sequence and kit for the method Download PDF

Info

Publication number
US20090298062A1
US20090298062A1 US12/067,710 US6771006A US2009298062A1 US 20090298062 A1 US20090298062 A1 US 20090298062A1 US 6771006 A US6771006 A US 6771006A US 2009298062 A1 US2009298062 A1 US 2009298062A1
Authority
US
United States
Prior art keywords
tail
sequence
length
probe
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/067,710
Other languages
English (en)
Inventor
Hidetoshi Tahara
Toshinori Ide
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Hiroshima University NUC
Original Assignee
Fujirebio Inc
Hiroshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc, Hiroshima University NUC filed Critical Fujirebio Inc
Assigned to HIROSHIMA UNIVERSITY, FUJIREBIO INC. reassignment HIROSHIMA UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IDE, TOSHINORI, TAHARA, HIDETOSHI
Publication of US20090298062A1 publication Critical patent/US20090298062A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • the present invention relates to a method of measuring the length of a G tail sequence and a kit for use in the method.
  • telomeres Human chromosomal DNA have double-stranded DNA with repeated sequences of 5′-TTAGGG-3′ at the terminus, which are called telomeres.
  • the terminal of the telomere has a structure in which the 3′-terminal is an overhang, and a single-stranded DNA region of 75 to 300 bases (G tail, hereinafter referred to simply as G tail).
  • G tail is normally in a protected state, as a loop is formed, except during the access of a telomere-elongating enzyme telomerase or during the replication of DNA (see, for example, Nonpatent Document 1).
  • a telomere double-stranded region occupying the most of the telomere is known to be shortened after each cell division and thus involved in cell aging, but the G tail retains a certain length of 75 to 300 bases even after repeated cell division.
  • a G tail retains a certain length of 75 to 300 bases after the termination of cell division by the shortening of a telomere double-stranded region after may cell divisions, i.e. after the limited replicative senescence, and some other reports showed that a G tail is shortened after the limited replicative senescence. This is probably because there was no method of measuring the length of a G tail accurately and quantitatively, as the G tail is much shorter than the telomere.
  • telomere G tail has a function completely different from that of a double-stranded region, i.e., it is involved in direct signaling of cell death, various cell responses, and the like, as described below.
  • telomere has telomere-binding proteins binding to the telomere; TRF1 (Telomere repeat binding factor) and TRF2 are known as such telomere-binding proteins; and it has been recently found that cancer cells do not form a G tail loop in the absence of TRF2 and consequently have shortened G tails (see, for example, Nonpatent Document 2). In such case, what is important is that the G tail is shortened, although the entire telomere length remains unchanged and also fused with the chromosome terminal.
  • TRF1 and TRF2 described above are known to be essential for the formation of a G tail loop.
  • DNA damage-sensitive signals e.g., caused for example by various DNA damaging agents or radiation, do not trigger the shortening of the telomere, but induce the shortening of the G tail. This is apparent, since proteins needed for DNA restoration (such as ATM, NBS1 and MRN) are recruited.
  • ATM is a gene responsible for angiectatic diseases
  • NBS1 is a gene responsible for Nijmegen syndromes, i.e., a rare autosomal recessive genetic disease characterized by its high carcinogenicity, immunodeficiency, chromosomal instability, and radiosensitivity. Therefore, the recruitment of these genes to the G tail suggests some relationship of the G tail with the above-described diseases. Actually, the inhibition of the function of TRF2 as the adhesive of a G tail loop induces ATM-dependent apoptosis (see, for example, Nonpatent Document 3).
  • a cancer-inhibiting gene product p53 of which many variants are observed in many cancers, is known to bind to a G tail (see, for example, Nonpatent Document 5), evidently indicating that the change in the G tail is a signal even in diseases associated with cancers and aging.
  • T-OLA telomere-oligonucleotide-ligation assay
  • PENT primary-extension/nick translation
  • 3′-overhang protection assay see, for example, Nonpatent Documents 6 and 7.
  • the G tail length which is approximately 1/100 or less of the entire telomere length, is within the range of its operation and measurement errors, and therefore cannot be measured.
  • the signal intensity of a G tail obtained by the method is so low at the noise level, it is difficult to determine the G tail quantitatively and accurately and also to identify whether the signal is specific to the G tail.
  • Patent Document 1 Japanese Unexamined Patent Publication No. 2001-95586
  • Nonpatent Document 2 van Steensel B, Smogorzewska A and de Lange T., Cell: 92 (1998), 401-13.
  • Nonpatent Document 3 Karlseder J, Broccoli D, Dai Y, Hardy S and de Lange T., Science: 283 (1999), 1321-5.
  • Nonpatent Document 4 Gomez D, Paterski R, Lemarteleur T, Shin-Ya K, Mergny J L and Riou J F., J. Biol. Chem.: 279 (2004), 41487-94.
  • Nonpatent Document 5 Stansel R M, Subramanian D and Griffith J D. J. Biol. Chem.: 277 (2002), 11625-8.
  • Nonpatent Document 6 Chai, W., Shay, J. W. & Wright, W. E., Mol. Cell Biol.: 25, 2158-2168 (2005).
  • Nonpatent Document 7 Saldanha, S. N., Andrews, L. G. & Tollefsbol, T. O., Eur. J. Biochem.: 270, 389-403 (2003).
  • Nonpatent Document 8 Nakamura, Y. et al., Clin. Chem.: 45, 1718-1724 (1999).
  • An objective of the present invention is to provide a method of measuring the length of the sequence of a telomere single-stranded overhang (hereinafter, referred to simply as G tail) specifically and rapidly at high sensitivity without tedious processing operation and denaturation, and a kit for use therein.
  • the inventors of the present invention have found that it is possible to determine the length of a G tail without the denaturation of a chromosomal DNA in a sample, by measuring chemiluminescence intensity through a particular HPA method, especially by measuring the G tail length quantitatively with a calibration curve drawn by using G tail oligomer standards.
  • the inventors also discovered the fact that the chemiluminescence is specific to the G tail and can be confirmed by a exonuclease treatment. That is, it is possible to determine the length under a condition with a higher ratio in luminescence intensity between the exonuclease treated and untreated samples, i.e., higher in a signal/noise (“S/N”) ratio. In addition, a sample concentration condition giving a higher S/N ratio also has been identified. Based on these findings, the inventors have achieved the present invention.
  • the present invention provides followings:
  • a method of measuring the length of a G tail sequence comprising hydrizing a G tail of an nondenatured chromosomal DNA in a sample with a labeled DNA probe having a sequence complementary to a telomere repeat sequence, measuring chemiluminescence from the hybridized DNA probe, and determining the length of the G tail sequence from the measured value.
  • sample is a cell pellet of blood, a cultured cell, a fresh tissue, a cryopreserved tissue or a formalin-fixed tissue.
  • a kit for measuring the length of a G tail sequence comprising at least a labeled DNA probe having a sequence complementary to an nondenatured telomere repeat sequence, a cytolytic solution, and a hydrolytic reagent.
  • kit according to Item 7 further comprising an exonuclease as a confirming agent.
  • kit according to Item 7 or 8 wherein the label is an acridinium ester, luminol, isoluminol, pyrogallol, protohemin, aminobutylethyl-n-isoluminol or aminohexylethyl-n-ethyl-isoluminol.
  • kits according to any one of Items 7 to 9, wherein the sequence complementary to the telomere repeat sequence is a base sequence represented by (CCCTAA) n (n is an integer of 1 to 10).
  • FIG. 1 is a chart showing the summary of a G tail measuring method according to the present invention.
  • FIG. 2 is a graph showing the results of a dose-response test between a 29-base AE-labeled G tail HPA probe and a 84-base single-stranded synthetic G tail.
  • FIG. 3 is a graph showing the results of a specificity confirmation test.
  • FIG. 4 is a graph showing the amount of an AE-based chemiluminescence in each combination.
  • FIG. 5 is a graph showing the results obtained by using a genomic DNA previously treated with ExoI before a G tail assay, and an untreated sample.
  • FIG. 6-1 is a graph showing the change in the amount of chemiluminescence that is dependent on a T7 exonuclease treatment period of an nondenatured DNA.
  • FIG. 6-2 is a graph in which the rlu value of FIG. 6-1 is converted to an average G tail length by using the calibration curve of FIG. 2 .
  • FIG. 7 is a graph showing the results of a sensitivity limit confirmation test (in particular, minimum length of a detectable CG tail).
  • FIG. 8 is a plot of the amount of chemiluminescence in an arbitrary unit.
  • FIG. 9 is a graph showing the results when the measuring method according to the invention is applied directly to a cell pellet of a SiHa cancer cell line.
  • FIG. 10 a is a graph showing the results obtained when the measuring method according to the invention is applied directly to each cell pellet.
  • FIG. 10 b is a graph showing the results obtained when, for comparison and confirmation, the measuring method according to the invention is applied after an nondenatured genomic DNA is isolated from each cell pellet.
  • FIG. 11 a is a graph showing the results of measuring a G tail by the measuring method according to the invention.
  • FIG. 11 b is a graph showing the results of measuring the total telomere length according to the measuring method described in Japanese Unexamined Patent Publication No. 2001-95586 as a Comparative Example.
  • FIG. 12 is a graph showing the linearity in the measurement of G tail length by using a mouse genomic DNA.
  • FIG. 13 is a graph showing G tail lengths observed in mouse tissues.
  • FIG. 14-1 is a plot showing the linearity in a mouse genomic DNA quantitative determination test by using an internal standard probe A1a.
  • FIG. 42 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe A1b.
  • FIG. 14-3 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe A2a.
  • FIG. 14-4 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe A2b.
  • FIG. 14-5 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe B2 — 1b.
  • FIG. 14-6 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe B2 — 2a.
  • FIG. 14-7 is a plot showing the linearity in the mouse genomic DNA quantitative determination test by using an internal standard probe B2 — 2b.
  • FIG. 15 is a graph showing the results of measuring the responsiveness of an AH-labeled G tail HPA probe and a single-stranded synthetic G tail on a 96-well plate.
  • the method of measuring the length of a tail sequence is a method of determining the length of the G tail sequence, by hybridizing the G tail with a plurality of labeled probes complementary to the telomere repeat sequence, constituting the G tail by using a hybridization protection assay (HPA) method, and using the amount of chemiluminescence emitted from a nonradioactively labeled substance bound to the probes as an indicator.
  • HPA hybridization protection assay
  • the HPA method is a method of using an oligomer labeled with a nonradioactive labeling substance as a probe and detecting luminescence from the nonradioactively labeled substance when the probe is hybridized to a targeted DNA or RNA.
  • the characteristics of the method is that a labeled substance of a free probe is selectively hydrolyzed and the labeling substance is inactivated, instead of a physical separation such as washing performed for the differentiation of a hybridized probe from a unhybridized free probe.
  • a targeted G tail is detected in a short period of time, and the length of the G tail sequence is determined by using the amount of chemiluminescence of the labeled substance as an indicator without a tedious operation such as the amplification of the targeted G tail by PCR and the like.
  • a G tail which is a single-stranded region in a double-stranded chromosomal DNA, is targeted, and therefore it is possible to use a cell pellet containing an nondenatured chromosomal DNA as a sample.
  • the cell pellet used as a sample is a pellet of cells recovered after the centrifugation of cells or tissues (e.g., at 1,000 G for 5 minutes).
  • the pellet may then be washed with a cold phosphate-buffered saline (PBS( ⁇ )) twice, frozen rapidly in liquid nitrogen, and stored in a frozen state in liquid nitrogen at low temperature (for example at ⁇ 80° C.).
  • PBS( ⁇ ) cold phosphate-buffered saline
  • a suspension solution may be mixed by pipetting and sheared with a 26G syringe before use.
  • the number of cells in the sample is preferably 1 ⁇ 100 to 3.5 ⁇ 10 6 , more preferably 3 ⁇ 10 5 to 7 ⁇ 10 5 , for the viewpoint of carrying out under a condition higher in the S/N ratio.
  • the amount of the nondenatured chromosomal DNA used is preferably 0.5 ⁇ g to 40 ⁇ g, more preferably 1 ⁇ g to 20 ⁇ g, and particularly preferably 3 ⁇ g to 7 ⁇ g.
  • the kind of the cell sample is not particularly limited, if it contains nondenatured chromosomal DNA's, and examples thereof include blood, cultured cells, and various tissues.
  • the tissue may be arbitrarily selected, independent of the origin of the organ.
  • it may be an tissue in organs such as a cerebral nerve system, muscle and skeleton system, digestive tissues, respiration system, hematopoietic system or lymphatic system.
  • the tissue may be any tissue, for example, a fresh tissue (immediately after sampling by biopsy), a cryopreserved tissue, or a formalin-fixed tissue.
  • the measuring method according to the present invention is useful not only for comparison and evaluation of G tail lengths among individuals, but also for comparison and evaluation of the G tail length of the blood or tissue cell among different tissues in a single individual.
  • the G tail lengths of a liver cell, cardiac muscle cell, cerebral nerve cell, and the like can be compared and evaluated in a single individual.
  • cancer-derived tissues include cancer tissues such as of colon cancer and liver cancer; and cancer cell lines such as cell lines of cervical duct cancer, colon cancer, liver cancer, cervical cancer, chronic myelofibrosis, glioblastoma, breast cancer, and fibrosarcoma; and typical examples thereof include SiHa, K562, HeLa, U937, U373MG, T98G, A172, MCF-7, HT-1080, LoVo, WiDr, SW857, and VA-4; and the like.
  • nondenatured chromosomal DNA As described above in the measuring method according to the invention, it is not necessary to purify an nondenatured chromosomal DNA from a cultured cell or a human tissue before use, because it is possible to use a cell pellet as it is, but a purified nondenatured chromosomal DNA may be used, as dissolved in a hybridization buffer described below.
  • the nondenatured chromosomal DNA may be purified by any method (see, for example, Tahara H., et al., Oncogene 15 (1997), 1911-1920).
  • the hybridization buffer which dissolves the sample, the probe described below, and the like is preferably a buffer which dissolves a cell membrane, a nuclear membrane, and others, because the cell itself may be used as a sample.
  • a lithium succinate buffer containing a laurylsulfate salt, lithium chloride, EDTA and EGTA, and the like examples thereof include a lithium succinate buffer containing a laurylsulfate salt, lithium chloride, EDTA and EGTA, and the like.
  • the labeled HPA probe for use in the present invention is an oligonucleotide having a base sequence represented by (CCCTAA) n (n is an integer of 1 to 10) that is labeled with at least one nonradioactive labeling substance.
  • n is properly selected according to a desired chromosomal DNA, but preferably 2 to 8, more preferably 3 to 5.
  • the oligonucleotide for use as a probe can be prepared by a commercially available DNA synthesizer by any DNA-producing method such as the phosphoamidite method.
  • an amino linker is preferably introduced for labeling with a nonradicoactive labeling substance.
  • reagents for the introduction of an amino linker when the phosphamidite method is used include, for example, the following linker-introducing reagents 1 to 3.
  • the oligonucleotide containing the introduced amino linker can be prepared, for example, according to the method described in Japanese Patent No. 3483829.
  • AE acridinium ester in the present invention
  • an oligonucleotide which introduced the amino linker by the reaction of an N-hydroxysuccinimide ester in the AE with an amino group in the amino linker introduced as described above, can be labeled.
  • a labeled HPA probe for use in the present invention is constructed
  • the labeling method with AE and the operation procedure can be performed, for example, according to the method described in Japanese Patent No. 3483829.
  • the labeling site for example with AE, can be determined arbitrarily according to the position of an amino linker introduced during DNA synthesis (Japanese Unexamined Patent Publication No. 2-502283).
  • Such a labeled HPA probe is available, for example, form Gene Probe Inc., and an example thereof is an AE-labeling G tail HPA probe (5′-CCCTAACCCTAACC*CTAACCCTAACCCTA-3′, SEQ ID No. 1, 29 bases). * indicates the AE labeling site, and, as described above, an amino group in an amino linker introduced to a oligonucleotide with the introducing reagent 1, 2 or 3 is labeled by the reaction with an N-hydroxysuccinimide ester in AE.
  • nonradicactive labeling substances include, in addition to the compound AE, lumiol, isoluminol, pyroallol, protohemin, aminobutylethyl-n-isoluminol and aminohexylethyl-n-ethyl-isoluminol.
  • the nonradioactive labeling substance has a substituent forming a chemical bond with the amino group in the amino linker introduced to the oligonucleotide. Examples of such a substituent group include, for example, a N-hydroxysuccinimide ester group.
  • X 1 represents a nitrogen, phosphorus, boron or arsenic atom
  • R 1 represents an alkoxy or aryloxy group or a substituted or unsubstituted alkyl alkenyl or aryl group
  • R 2 represents a hydrogen atom, an alkoxy or aryloxy group, a substituted or unsubstituted alkyl, alkenyl or aryl group, or a group represented by the following General Formula (III):
  • X 2 represents an oxygen or sulfur atom; and R 2 is the same as that above;
  • Y represents an oxygen or sulfur atom or a NH group;
  • R 3 represents a hydrogen atom, an amino, hydroxy, thiol, carboxylic acid, halogen, nitro, alkoxy or aryloxy group, or a substituted or unsubstituted acetyl, alkyl, alkenyl or aryl group;
  • R 4 represents a substituted or unsubstituted alkyl, alkenyl or aryl group; and at least one group of R 1 , R 2 , R 3 and R 4 contains a reactive site forming a chemical bond with the amino linker.
  • examples of the halogen include, for example, a fluorine, chlorine, bromine, iodine or astatine atom.
  • the alkyl groups are those having 1 to 20 carbon atoms, preferably 1 to 5 carbon atoms, such as methyl, ethyl, propyl, butyl, amyl and the like.
  • the alkenyl groups are those having 1 to 10 carbon atoms, preferably having 1 to 5 carbon atoms, such as example vinyl, allyl and the like.
  • the aryl groups are, for example, phenyl, tolyl, naphthyl, xylyl and the like.
  • the alkoxy groups are, for example, those having 1 to 10 carbon atoms, preferably having 1 to 5 carbon atoms, such as methoxy and ethoxy; and the aryloxy groups are, for example, phenoxy, naphthoxy and the like.
  • FIG. 1 is a chart showing the summary of the G tail measuring method according to the present invention, in which reference numeral 1 represents a G tail; reference numeral 2 represents a telomere G-strand; reference numeral 3 represents a telomere C-strand; reference numeral 4 represents a double-stranded telomere region, reference numeral 5 represents a labeled (HPA) probe, reference numeral 6 represents the compound AE, reference numeral 7 represents an unhybridized probe; and reference numeral 8 represents a probe inactivated by hydrolysis.
  • the G tail 1 is located at the terminal of the G-strand of the telomere double-stranded region 4 consisting of chromosomal DNA terminal of the telomere G-strand 2 and C-strand 3 .
  • the AE-labeled probe 5 for use in the present invention is labeled with the AE 6 and has a sequence complementary to a repeat sequence in the G tail, and the probes in the number corresponding to the repetition number of the repeat sequences are bound thereto by hybridization, as shown in FIG. 1( a ).
  • the hybridization between the AE-labeled probe 5 and the G tail 1 is specifically performed by adding a hybridization solution containing the AE 6 —labeled probe to a cell pellet and then incubating the mixture, for example, at 60 to 65° C. for 5 to 30 minutes (heated incubation).
  • the AE-labeled probe 5 hybridized with the G tail 1 has the AE stabilized; the ester bond of the AE remains protected even after hydrolysis for a certain period in FIG. 1( b ); the addition of an alkali and hydrogen peroxide leads to chemiluminescence; and thus, it is possible to determine the length of the G tail 1 by measuring the amount of luminescence quantitatively, as shown in FIG. 1( c ).
  • the AE is not stabilized.
  • the ester bond of the AE is hydrolyzed, giving an inactivated probe 8 that shows no chemiluminescence, thus prohibiting the detection of the inactivated probe 8 .
  • a hydrolysis reagent is added, and the mixture is incubated at 60° C. for 5 to 10 minutes.
  • the measurement of chemiluminescence of the AE in FIG. 1( c ) after incubation is carried out by using a luminometer (for example, Leader I (trade name, manufactured by Gene Probe Inc.)).
  • a luminometer for example, Leader I (trade name, manufactured by Gene Probe Inc.)
  • the use of a 96-well luminometer is preferable for high-throughput screening by using the measuring method according to the invention.
  • the chemiluminescence is C tail-specific by eliminating a G tail sequence selectively by treating a DNA sample with an exonuclease I (ExoI) in such a manner that exonuclease removes a single-stranded nucleotide in the 3′ to 5′ direction.
  • ExoI exonuclease I
  • the ratio of the signal of the ExoI-unpretreated sample to that of the ExoI-treated sample may be calculated as an S/N ratio.
  • the chemiluminescence is G tail sequence-specific, by treating the G tail with T7 exonuclease, removing the telomere C-strand 3 in the 5′ to 3′ direction, and elongating the G tail on the telomere G-strand 2 .
  • the G tail has sequences obtained by repeating a base unit sequence (5′-TTAGGG-3′) 24 times and the probe is [5′-(CCCTAA) 4 -3′] in which a (5′-CCCTAA-3′) sequence is repeated four time, theoretically, six probes hybridize to the G tail. Accordingly, labels corresponding to six probes is detected. It is possible to calculate the length of the G tail sequence, by previously drawing a calibration curve by determining the label intensity when the probe is hybridized with standard DNA reagents of known lengths.
  • the length of the G tail by measuring the chemiluminescence intensity quantitatively, when an acridine derivative other than AE or another nonradioactive labeling substance (e.g., luminol, isoluminol, pyrogallol, protohemin, aminobutylethyl-n-isoluminol, or aminohexylethyl-n-ethyl-isoluminol) is used as the label.
  • an acridine derivative other than AE or another nonradioactive labeling substance e.g., luminol, isoluminol, pyrogallol, protohemin, aminobutylethyl-n-isoluminol, or aminohexylethyl-n-ethyl-isoluminol
  • a probe labeled with the acridine derivative or another nonradioactive labeling substance is allowed to react with the cell pellet in a suitable amount; after the reaction, the mixture is processed, for example, by hydrolysis; and then, the amount of chemiluminescence is determined quantitatively.
  • the kit according to the present invention is a set containing at least a labeled DNA probe having a sequence complementary to an nondenatured telomere repeat sequence (e.g., (CCCTAA) n (n is an integer of 1 to 10)), a cytolytic solution, and a hydrolytic reagent.
  • a labeled DNA probe having a sequence complementary to an nondenatured telomere repeat sequence e.g., (CCCTAA) n (n is an integer of 1 to 10)
  • CCCTAA nondenatured telomere repeat sequence
  • Examples of the cytolytic solution include, for example, a lithium succinate buffer containing a laurylsulfate salt, lithium chloride, and EDTA and EGTA.
  • Examples of the hydrolytic reagent include, for example, a tetrasodium borate buffer containing Triton X-100.
  • the kit according to the present invention preferably contains a standard for the formation of a G tail length calibration curve (G tail sequence preferably having 20 bases or more, more preferably 30 to 100 bases).
  • G tail sequence preferably having 20 bases or more, more preferably 30 to 100 bases.
  • the kit more preferably contains a standard for the formation of a calibration curve for the normalization of a chromosomal DNA amount (synthetic Alu-sequence DNA preferably having 20 bases or more, more preferably 30 to 100 bases) and an Alu-HPA probe for the normalization of the chromosomal DNA amount (e.g., 5′-TGTAATCCCA*GCACTTTGGGAGGC-3′; *: AE-labeling site, SEQ ID No. 2).
  • a standard for the formation of a calibration curve for the normalization of a chromosomal DNA amount synthetic Alu-sequence DNA preferably having 20 bases or more, more preferably 30 to 100 bases
  • an Alu-HPA probe for the normalization of the chromosomal DNA amount (e.g., 5′-TGTAATCCCA*GCACTTTGGGAGGC-3′; *: AE-labeling site, SEQ ID No. 2).
  • the kit still more preferably contains an exonuclease (e.g., ExoI, T7 exonuclease, or the like, preferably ExoI) as a confirming agent.
  • an exonuclease e.g., ExoI, T7 exonuclease, or the like, preferably ExoI
  • the kit may contain additionally, for example, a purified chromosomal DNA of any cancer cell as a positive control DNA.
  • the Alu sequence is a base sequence represented by 5′-GCCTCCCAAAGTGCTGGGATTACA-3′ (SEQ ID No. 3), the amount of which in the chromosomal DNA is known to be constant also in cultured cell (J. D. Watson Ed., Molecular Biology of the Gene, p. 668). It is possible to determine the amount of the G tail sequence in a certain amount of the chromosomal DNAs, by measuring the amount of the Alu sequence added as an internal standard to each sample and determining the rate of the G tail sequence and the Alu sequence during the measurement or the G tail. In this way, it is possible to calculate the average length of the G tail sequence.
  • the traditional methods demand a radioactive label (RI) and gel preparation, which are troublesome in handling and require electrophoretic separation which demands an elongated period. Therefore, these methods are tedious assays demanding at least two days for completion, and cells can not be used without processing for measurement. In addition, these traditional methods may be applied to high-throughput screening for analyzing a great number of samples.
  • RI radioactive label
  • gel preparation which are troublesome in handling and require electrophoretic separation which demands an elongated period. Therefore, these methods are tedious assays demanding at least two days for completion, and cells can not be used without processing for measurement.
  • these traditional methods may be applied to high-throughput screening for analyzing a great number of samples.
  • the method according to the present invention which does not used radioactive materials, does not demand any special waste-processing facility or an electrophoretic device or the like for the separation of the reactive products and the unreacted radioactive materials. It is also possible to measure short length G tails of up to 20 nucleotides specifically, quantitatively and at high sensitivity, by using a single container (e.g., test tube), within a short period (about 40 minutes or less) from the collection of the tissues. In addition, it is possible to determine the length of the G tail reproducibly, as the measurement results are less dispersed and to handle a great number of samples easily. Furthermore, the measuring method according to the present invention allows the measurement not only of nondenatured chromosomal DNAs but also of cells directly, and is thus applicable to the high-throughput screening for analyzing a great number of samples.
  • a genomic DNA may be collected not in an intact (uncleaved) state, and thus, it is possible to determine the G tail length of cultured cells, fresh tissues, and others, as well as tissues stored for a long period (e.g., formalin-fixed tissues). Furthermore, by the method according to the present invention, it is possible to obtain detection results high in sensitivity than those obtained by conventional detection methods. Specifically, the sensitivity with a purified DNA is about 1000 times higher than that of the Southern method, and the method of the present invention allows analysis of several (ng) of a genomic DNA.
  • the advantageous effects of the present invention will be described.
  • the method of measuring the length of a G tail sequence according to the present invention it is possible to measure a short-length G tail of up to 20 nucleotides specifically and quantitatively at high sensitivity, only in 3 steps without the denaturation of a telomere or any tedious processing.
  • the measuring method according to the present invention allows analysis not only of nondenatured chromosomal DNAs but also of cells directly as samples and thus, acceleration of analysis, and is applicable, for example, to the high-throughput screening for analyzing a great number of samples.
  • the method of the present invention is useful in the cases where the number of the cells obtained is limited, for example, during blood test or analysis of clinical samples such as biopsy and urine for cancer cell analysis.
  • kit for measuring the length of a G tail sequence it is possible to measure the length of the G tail sequence in a sample within 40 minutes by using only a single container (e.g., test tube).
  • the measuring method according to the present invention can be used clinically for patients with various diseases associated with cancer and aging, which may proceed as a result of G tail loss.
  • the measuring method according to the invention is useful in basic research on cancer, aging, and the biological impacts caused by telomere abnormality.
  • rlu chemiluminescence
  • the AE-labeled G tail probe was prepared by labeling, with AE, an amino linker-introduced oligonucleotide (SEQ ID No. 1) prepared by using the linker-introducing reagent 3, according to the method described in Japanese Patent No. 3483829.
  • EDTA represents ethylenediaminetetraacetic acid
  • EGTA represents ethylene glycol bis(2-aminoethylether)tetraacetic acid.
  • the hydrolysis of the AE in an unhybridized probe was performed by charging 300 ⁇ L of a hydrolysis buffer (0.6 mol/L tetrasodium borate buffer containing 50 mL/L of Triton X-100, pH 8.5) into each reaction tube, stirring the mixture vigorously with a Vortex mixer, and incubating the mixture at 60° C. for 10 minutes.
  • the AE in the hybridized probe was not hydrolyzed under the above-described condition.
  • These tubes were cooled on ice for 1 minute or more, and the chemiluminescence in each tube was measured with a luminometer (trade name: Leader 1, manufactured by Gene Probe Inc.) for 2 seconds.
  • FIG. 2 is a graph showing the results of the dose-response test carried out between the 29-base AE-labeled G tail HPA probe and the single-stranded synthetic G tail (84 bases). As apparent from FIG. 2 , increase in oligonucleotide dosage in the range of 0.05 in to 10 fmol is accompanied by a linear increase of signal intensity.
  • WT [5′-(TTAGGG) 14 -3′]; variant G tail oligonucleotide A [5′-(TTGGGG) 14 -3′]; variant G tail oligonucleotide B [5′-(TTAAGG) 14 -3′]; variant G tail oligonucleotide C [5′-(TTCGGG) 14 -3′]; and variant G tail oligonucleotide D [5′-(TTAGGC) 14 -3′](all G tail DNAs from Prorigo).
  • FIG. 3 is a graph showing the results of the specificity confirmation test.
  • WT represents a wild-type single-stranded G tail sequence
  • the variant G tail nucleotide A represents 5′-(TTGGGG) 4-3 ′
  • the variant G tail nucleotide B represents 5′-(TTAAGG) 14 -3′
  • the variant G tail nucleotide C represents 5′-(TTCGGC) 14 -3′
  • the variant G tail nucleotide D represents 5′-(TTAGGC) 14 -3′
  • NC represents a negative control.
  • NC represents the background signal level in the test.
  • the HPA probe for use in the present invention detects the desired mammal G tail sequence specifically at a high S/N ratio.
  • a test for confirming an alkali treatment resistance of AE was performed, to know how many complete nucleotide base pairs are needed for the hybridization between the G tail and the AE-labeled G tail HPA probe (29 bases) for the chemiluminescence of the AE.
  • FIG. 4 is a graph showing the amount of chemiluminescence in each combination on the basis of that of the AE.
  • FIG. 4 there was almost no chemiluminescence detected in combinations mismatched at the AE-labeling site (iv) and mismatched at the position one base separated from the AE-labeling site (iii).
  • the position five bases separated from the AE-labeling site is mismatched ((ii) and (v))
  • there was only slight deterioration in chemiluminescence The results indicated that mismatching at a position about six bases separated from the AE-labeling site had no influence on HPA chemiluminescence.
  • SiHa cancer cell line-derived nondenatured genomic DNA samples in various amounts (u, 3 ⁇ g, 5 ⁇ g, 10 ⁇ g and 20 ⁇ g and the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu were hybridized with each other.
  • the total amount of the DNA solution in a Falcon 352053 tube (trade name) was adjusted to 100 ⁇ L with sterile water or a TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0).
  • the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu dissolved in 100- ⁇ L of the hybridization buffer was added to the DNA solution, and the mixture was stirred thoroughly with a Vortex mixer and incubated at 60° C. for 20 minutes.
  • the hydrolysis of the AE in unhybridized probe and the detection of the chemiluminescence were performed under a condition similar to that in ⁇ 1-2>.
  • the nondenatured genomic DNA may not be isolated for use, but the nondenatured genomic DNA used in the confirmation test ⁇ 4-1> was previously isolated in the following manner:
  • the nondenatured genomic DNA used for G tail length measurement was isolated from each cell line by using the phenol-chloroform extraction method. Specifically, cells were centrifuged in an Eppendorf-micro centrifuge tube at 6,000 rpm and 4° C. for 5 minutes, to give a pellet in the microtube. The pellet was washed once with PBS( ⁇ ) and resuspended in an extraction buffer containing 10 mM Tris buffer (pH 7.6), 150 mM NaCl and NP-40, to a final concentration of 0.5% . After proteinase K digestion, phenol-chloroform extraction was performed twice. The genomic DNA as precipitated with ethanol, treated with RNase A, and then, dissolved in a TE buffer.
  • the nondenatured genomic DNA was treated with exonuclease I (ExoI) that removes a single-stranded nucleotide selectively in the 3′ to 5′ direction, eliminating the G tail sequence selectively, consequently confirming that the chemiluminescence was G tail-specific.
  • the exonuclease I treatment of the nondenatured genomic DNA was performed in the following manner: The genomic DNA was treated with ExoI (manufactured by New England Biolabs, 0.2 U/ ⁇ g-DNA) in 1 ⁇ exonuclease buffer (67 mM glycine-KOH (pH 9.5), 6.7 mM MgCl 2 , 10 mM 2-mercaptoethanol) at 37° C. for 2 hours, and the exonuclease was inactivated under heat at 80° C. for 20 minutes before the G tail assay.
  • ExoI exonuclease I
  • FIG. 5 is a graph showing the results obtained by using the genomic DNA previously treated with ExoI before a G tail assay and that not treated therewith. It is a graph obtained by plotting the total genomic DNA amount normalized into arbitrary unit, obtained by denaturing a 1/20 amount of the nondenatured genomic DNA by the method described below and hybridizing it with the AE-labeled Alu probe in an amount of 3 ⁇ 10 6 rlu. As apparent form FIG. 5 , a linear response was observed at the nondenatured genomic DNA amount in the range of 1 ⁇ g to 20 ⁇ g. The results indicate that 5 ⁇ g of nondenatured genomic DNA may be used normally.
  • FIG. 5 is a graph showing the results obtained by using the genomic DNA previously treated with ExoI before a G tail assay and that not treated therewith. It is a graph obtained by plotting the total genomic DNA amount normalized into arbitrary unit, obtained by denaturing a 1/20 amount of the nondenatured genomic DNA by the method described below and hybridizing it with the
  • the nondenatured genomic DNA was treated with T7 exonuclease, eliminating the telomere C-strand in the 5′ to 3′ direction and elongating the G tail in the telomere G-strand, consequently revealing that chemiluminescence was G tail-specific.
  • the SiHa cancer cell line-derived nondenatured genomic DNA (5 ⁇ g) was treated with T7 exonuclease in the following manner: The genome DNA was incubated with T7 exonuclease (manufactured by New England Biolabs, 1 U/ ⁇ g-DNA) in 1 ⁇ NE Buffer 4 (50 mM potassium acetate, 20 mM Tris acetate, mM magnesium acetate, 1 mM dithiothreitol, pH 7.9) at 25° C. for the period shown in the Figure. The reaction was terminated by addition of EDTA (pH 8.0) to a final concentration of 25 mM.
  • T7 exonuclease manufactured by New England Biolabs, 1 U/ ⁇ g-DNA
  • 1 ⁇ NE Buffer 4 50 mM potassium acetate, 20 mM Tris acetate, mM magnesium acetate, 1 mM dithiothreitol, pH 7.9
  • the incubation and hybridization of the AE-labeled G tail HPA probe and the nondenatured DNA the hybridization buffer for the detection of the G tail were performed under a condition similar to that in ⁇ 4-1> above.
  • the hydrolysis of the AE in the unhybridized probe and detection of the chemiluminescence were performed under a condition similar to that in ⁇ 1-2>.
  • FIG. 6-1 is a graph showing the change in the amount of chemiluminescence that is dependent on the T7 exonuclease treatment period of the nondenatured DNA.
  • the comparison of the ExoI-treated graph and the ExoI-unpretreated graph shows that an extremely large S/N ratio can be obtained.
  • FIG. 6-2 is a graph in which the rlu value of FIG. 6-1 is converted to an average G tail length by using the calibration curve of FIG. 2 .
  • the amount of chemiluminescence increased as the G tail sequence increased, in the proportion with the period of a T7 exonuclease treatment for the removal of telomere C-strand in the 5′ to 3′ direction.
  • the SiHa cancer cell line normally has a G tail sequence having an average length of approximately 220 nt (nt: number of nucleotides).
  • nt number of nucleotides.
  • the sensitivity limit of the measuring method according to the invention was determined, by using synthetic telomere terminal constructs (T7 TEL_Gt10, Gt20, Gt26, Gt43 and Gt62) having 10 nt, 20 nt, 26 nt, 43 nt and 62 nt G tails respectively.
  • Synthetic telomere terminal constructs in amounts of 0.5, 1.0, 5.0 and 10 fmol were used in respective tests (measurement: twice).
  • Synthetic telomere terminal constructs were prepared respectively by annealing DNA of SEQ ID No. 8 and DNAs of SEQ ID Nos. 9 to 13 (all, manufactured by Prorigo) and purifying the DNAs by gel electrophoresis.
  • the incubation and hybridization of the AE-labeled G tail HPA probe and the nondenatured DNA in the hybridization buffer for detection of G tail were performed under a condition similar to that in ⁇ 4-1> above.
  • the hydrolysis of the AE inunhybridized probe and detection of the chemiluminescence were performed under a condition similar to that in ⁇ 1-2>.
  • FIG. 7 is a graph showing the results of the sensitivity limit confirmation test.
  • the nondenatured DNA used in the measurement test according to the present invention was denatured thermally and hybridized by using an Alu-HPA probe.
  • the Alu-HPA probe used was 5′-TGTAATCCCA*GCACTTTGGGAGGC-3′ (*: AE-labeled site, SEQ ID No. 2).
  • the Alu-HPA probe was prepared by labeling the amino linker-introduced oiligonucleotide (SEQ ID No. 2) prepared by using the linker-introducing reagent 3, with AE according to the method described in Japanese Patent No. 3483829.
  • FIG. 8 is a plot of the amount of chemiluminescence in an arbitrary unit (measurement; thrice). As is apparent from FIG. 8 , a linear response was observed in regard to the amount of chemiluminescence of the Alu DNA sequence at genomic DNA concentrations in the range of 0.005 ⁇ g to 1 ⁇ g.
  • the SiHa cancer cell line pellet prepared in the section ⁇ 8-2> below for the measurement of the length of the G tail in cell pellet was resuspended in 100 ⁇ L of the hybridization buffer above, and the suspended solution was mixed by pipetting and sheared with a 26G syringe before use.
  • the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu and the cell pellet were incubated and hybridized under a condition similar to that in ⁇ 4-1> above. Hydrolysis and chemiluminescence detection of the AE in the unhybridized probe were performed under a condition similar to that in ⁇ 1-2> above.
  • the cell pellet (1/10 volume) was denatured similarly to ⁇ 7-1> above and hybridized with 3 ⁇ 10 6 rlu of the AE-labeled Alu probe, for normalization of the total genomic DNA amount.
  • a cell pellet of a SiHa cancer cell line was prepared by collecting cells after the centrifugation of the SiHa cancer cell line at 1,000 G for 5 minutes, washing the cells with cold PBS( ⁇ ) twice, and freezing the cells rapidly in liquid nitrogen. The cell pellet was stored frozen at ⁇ 80° C. until use.
  • FIG. 9 is a graph showing the results when the measuring method according to the invention is applied directly to a cell pellet of a SiHa cancer cell line (measurement: twice).
  • the average G tail length of the SiHa cancer cell line was 220 nt.
  • FIG. 9 there was observed favorable linearity of the measuring method according to the invention in the cell concentration range of 1 ⁇ 10 5 to 3.5 ⁇ 10 6 cells, indicating that a cell pellet containing about 5 ⁇ 10 5 cells can favorably be used for G tail measurement.
  • the G tail measuring method according to the present invention was applied directly to various cell pellets (various TIG-3 human fibroblasts, various SV40-transformed cells and various SiHa cancer cells) each containing 5 ⁇ 10 5 cells; the G tail length of each cell was determined; and the biological properties of the cells were evaluated from the difference in G tail length among the cells.
  • Each cell pellet (5 ⁇ 10 5 cells) prepared similarly to ⁇ 8-2> above was resuspended in 100 ⁇ L of the hybridization-buffer, and the suspended solution was mixed by pipetting and sheared with a 26G syringe before use.
  • the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu and the cell pellet were incubated and hybridized under a condition similar to that in ⁇ 4-1> above. Hydrolysis and chemiluminescence detection of the AE in the unhybridized probe were performed under a condition similar to that in ⁇ 1-2> above.
  • the cell pellet (1/10 volume) was denatured similarly to ⁇ 7-1> above and hybridized with 3 ⁇ 10 6 rlu of an AE-labeled Alu probe, for normalization of the total genomic DNA amount.
  • the nondenatured genomic DNA was isolated from each of the cell pellets (various TIG-3 human fibroblasts, various SV40-transformed cells and various SiHa cancer cells) according to a method similar to that in ⁇ 4-2>, and the measuring method according to the invention was applied to the nondenatured genomic DNA of each cell.
  • TIG-3, SVts9-3 (SV40-transformed TIG-3), TIG-3-hTERT (human telomerase reverse transcriptase (hTERT) cDNA-infected TIG-3), human cervical duct cancer cell line SiHa, and retrovirus packaging cell line PT67 were cultured in a Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (manufactured by HyClone).
  • DMEM Dulbecco's Modified Eagle's Medium
  • a pBabe-N-mycTRF2 ⁇ B ⁇ M retrovirus construct for preparation of a retrovirus supernatant obtained from Prof. Titia de Lange, Rockfeller University and prepared according to the method described in van Steensel B, Smogorzewska A and de Lange T., Cell, 92 (1998), 401-13
  • a PT67 packaging cell line manufactured by BD Clontech
  • FuGene 6 transfection reagent manufactured by Roche
  • the supernatant was recovered; polybrene was added to a final concentration of 6 ⁇ g/ml; and the mixture was filtered through a 0.22 ⁇ m filter (manufactured by Millipore). The filtered supernatant was used for infection to the SiHa cancer cell line. On the next day, the medium was replaced with a fresh puromycin-containing (0.5 ⁇ g/ml) complete medium, and the mixture was cultured for 4 days, to give a TRF2 ⁇ B ⁇ M -infected SiHa cell line.
  • FIG. 10 a is a graph showing the results obtained when the measuring method according to the invention was applied directly to each cell pellet.
  • FIG. 10 b is a graph showing the results obtained when, for comparison and confirmation, the measuring method according to the invention was applied after the nondenatured genomic DNA is isolated from each cell pellet.
  • each right bar shows the result of G tail measurement after ExoI treatment for confirmation of telomere G tail-specific chemiluminescence, while each left bar, the result without ExoI pretreatment.
  • TIG-3(Y) represents a young cell having a cell population doubling level (PDL) of 28
  • TG-3(S) represents a aged cell having a PDL of 81
  • TG-3-hTERT represents a hTERT-introduced cell
  • SVts9-3 (50) represents a young SV40-transformed cell having a PDL of 50
  • SVts9-3 (121) represents a cell in the catastrophic state having a PDL of 121
  • SiHa represents a control vector-infected SiHa cell
  • SiHa dn TRF2 represents a dominant negative allelic gene (TRF2, -infected SiHa cell.
  • the average telomere G tail length was shortened especially in the SV40-transformed crisis cell, which is in good agreement with the traditional finding that the human telomere G tail shorten in the crisis stage (see, for example, Nonpatent Document 6).
  • the TRF2 dominant negative allelic gene (TRF2 ⁇ B ⁇ M ) is known to shortening of the G tail length (see, for example, Nonpatent Document 2), and the results on an SiHa cell confirmed the expected shortening of a G tail.
  • the results above showed that the measuring method according to the invention could be used for direct measurement of G tail length by using a cell pellet and also for biological evaluation from the intercellular difference of the measured G tail length.
  • the dominant negative allelic gene (TRF2 ⁇ B ⁇ M ) was infected to various cells (HeLa cancer cell, SiHa cancer cell, MCF-7 cancer cell, MRC-5-hTERT normal fibroblast, and 90p normal mammary epithelial cell) according to a method similar to that in ⁇ 9-3>;
  • the nondenatured DNA was isolated from each cell (HeLa cancer cell, SiHa cancer cell, MCF-7 cancer cell, MRC-5-hTERT normal fibroblast, and 90p normal mammary epithelial cell) according to a method similar to that in ⁇ 4-2>;
  • the nondenatured DNA (5 ⁇ g) was used in the G tail measuring method according to the present invention for measurement of the G tail length; and, as a Comparative Example, the measuring method described in Japanese Unexamined Patent Publication No.
  • FIG. 11 a is a graph showing the results of measuring G tail by the measuring method according to the invention.
  • FIG. 11 b is a graph showing the results of measuring the total telomere length by the measuring method described in Japanese Unexamined Patent Publication No. 200-95586 as a Comparative Example.
  • “C” represents a control
  • “T” represents a cell treated with a G tail-shortening medicine telomestatin (5 ⁇ m) for 48 hours
  • + represents a ExoI-treated cell
  • ⁇ represents an untreated cell.
  • Comparison of the ExoI-treated graph with the ExoI-unpretreated graph reveals that an extremely large S/N ratio is obtained.
  • “C” represents a control
  • T represents a cell previously treated with a G tail-shortening medicine telomestatin (5 ⁇ m) for 48 hours.
  • FIGS. 11 a and 11 b will be described briefly.
  • the values (arbitrary unit) on the ordinate axis were determined as the ratios of the measured luminescence intensity to the internal standard Alu sequence by using the same probe and the same instrument, and thus, FIG. 11 a and 11 b can be compared and evaluated.
  • the comparison of FIGS. 11 a and 11 b shows that the arbitrary intensities were approximately 2 in FIG. 11 a while the arbitrary intensities about 70 in FIG. 11 b , revealing that the signal intensity in FIG. 11 a is only approximately 1/35 of that in FIG. 11 b .
  • the nondenatured DNA was used in an amount of 5 ⁇ g in FIG. 11 a , compared to 0.5 ⁇ g in FIG. 11 a , and thus, the ratio is approximately 1/350 under the same concentration.
  • the length of the G tail which is 75 to 300 bases, is significantly smaller than that of the telomere having an entire length of 4 kbp to dozens kbp, even if the chromosome terminal G tail was shortened forcibly with telomestatin, for example by about 100 bases, it was not possible to observe the difference by the traditional telomere HPA method, i.e., the method described in Patent Document (Japanese Uexamined Patent Publication No 2001-95586). Alternately as apparent from Table 3 and FIG.
  • the nondenatured genomic DNA may not be isolated for use, but the nondenatured genomic DNA used in the confirmation test ⁇ 11-2> was previously isolated in the following manner:
  • the nondenatured genomic DNA used for G tail length measurement was isolated from each cell line by using phenol-chloroform extraction method. Specifically, cells were centrifuged in an Eppendorf micro centrifuge tube at 6,000 rpm and 4° C. for 5 minutes, to give a pellet in the microtube. The pellet was washed once with PBS( ⁇ ) and resuspended in an extraction buffer containing 10 mM Tris buffer (pH 7.6), 150 mM NaCl and NP-40, to a final concentration of 0.5%. After proteinase K digestion, phenol-chloroform extraction was performed wice. The genoic DNA was precipitated with ethancl treated with RNase A, and vhen, dissolved in a TE buffer.
  • NIH3T3 mouse fibroblast-derived nondenatured genomic DNA samples in various amounts (0.001 ⁇ g, 0.003 ⁇ g, 0.005 ⁇ g, 0.01 ⁇ g, 0.03 ⁇ g, 0.05 ⁇ g, 0.1 ⁇ g, 0.3 ⁇ g, 0.5 ⁇ g, 1 ⁇ g, 3 ⁇ g, 5 ⁇ g and 10 ⁇ g) and the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu were hybridized with each other.
  • telomere 3′-tail a genomic DNA
  • the total amount of the DNA solution in a Falcon 352053 tube was adjusted to 100 ⁇ L with sterile water or a TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0).
  • the mixture was heated at 65° C. in a water bath for 5 minutes; the AE-labeled G tail HPA probe in an amount of 3 ⁇ 10 6 rlu dissolved in 100- ⁇ L of the hybridization buffer was added to the DNA solution; and the mixture was stirred thoroughly with a Vortex mixer and incubated at 60° C. for 20 minutes. Hydrolysis of the AE in unhybridized probe and detection of the chemiluminescence were performed under a condition similar to that in ⁇ 1-2>.
  • the nondenatured genomic DNA may not be isolated for use, but the nondenatured genomic DNA used in the confirmation test ⁇ 12-1> was previously isolated in the following manner:
  • the nondenatured genomic DNA used for G tail length measurement was isolated from each tissue by using phenol-chloroform extraction method. Specifically, each tissue, which was stored frozen at ⁇ 80° C., was thawed, homogenized immediately, and resuspended in an extraction buffer containing 10 mM of Tris buffer (pH 7.6), 150 mM of NaCl, and NP-40, to a final concentration of 0.5%. After proteinase K digestion, phenol-chloroform extraction was performed twice. The genomic DNA was precipitated with ethanol, treated with RNase A, and then, dissolved in a TE buffer.
  • telomere 3′-tail (G tail) the total amount of the DNA solution in a Falcon 352053 tube (trade name) was adjusted to 100 ⁇ L with sterile water or a TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8.0). The mixture was heated at 65° C.
  • FIG. 13 shows that all samples were ExoI-sensitive which confirmed that the detected chemiluminescence was specific to the single-stranded G tail, while the comparison of the ExoI-treated graph and the ExoI-unpretreated graph shows that it is possible to measure the G tail sufficiently also in mouse tissues.
  • the nondenatured DNA used in the measurement test according to the present invention was denatured thermally and hybridized by using an A1, A2 or B2-HPA probe.
  • the A1, A2 or B2-HPA probe used was A1a probe: 5′-GAA CAG TGT ATA T*C AAT GAG TTA CAA T-3′ (SEQ ID No.
  • A1b probe 5′-GAA CAG TGT ATA TCA A*T GAG TTA CAA T-3′ (SEQ ID No. 15); A2a probe: 5′-CGT TGG AA* ACG GGA TTT GTA GAA CA-3′ (SEQ ID No. 16); A2b probe: 5′-CGT TGG AAA CGG GA* TTT GTA GAA CA-3′ (SEQ ID No. 17); B21b probe: 5′-GTC TGA AGA CA* GCT ACA GTG TA-3′ (SEQ ID No. 18); B2-2a probe: 5′-CCG ACT G*C TCT TCT GAA GGT C-3′ (SEQ ID No. 19); or B2 — 2b probe: 5′-CCG ACT GCT CTT C*T GAA GGT C-3′ (SEQ ID No. 20) (in sequences above, “*” represents the AE-labeling site).
  • the A1, A2 or B1-HPA probe was prepared by labeling the amino linker-introduced oligonucleotide (SEQ ID No. 2) prepared by using the linker-introducing reagent 3 according to the method described in Japanese Patent No. 3483829 with AE.
  • FIGS. 14-1 to 14 - 7 are clots of the amount of chemiluminescence in and arbitrary unit (measurement: thrice). As apparent from FIGS. 14-1 to 14 - 7 , it was possible obtain linear response in chemiluminescence by the A1, A2 or B2 DNA sequence in the genomic DNA concentration range of 0.5 ⁇ g to ⁇ g.
  • the following hybridization buffer diluents (30 ⁇ L) containing a synthetic single-stranded G tail, 84 bases, 5′-(TTAGGG) 14 -3′ (manufactured by Prorigo) at various concentrations and an AE-labeled G tail HPA probe (5′-CCCTAACCCTAACC*CTAACCCTAACCCTA-3′, SEQ ID No.
  • the AE-labeled G tail probe was prepared by labeling the amino linker-introduced oligonucleotide (SEQ ID No. 1) prepared by using the linker-introducing reagent 3, with AE according to the method described in Japanese Patent No. 3483829.
  • the hydrolysis of the AE in the unhybridized probe was performed by charging 90 ⁇ L of a hydrolysis buffer (0.6 mol/L tetrasodium borate buffer containing 50 mL /L of Triton X-100, pH 8.5) into each reaction tube, stirring the mixture thoroughly, and incubating the mixture at 70° C. for 25 minutes on a plate block heater.
  • the AE in hybridized probe was not hydrolyzed under the condition.
  • FIG. 15 is a graph showing the results of a dose-response test on G tail measurement carried out on a 96-well plate by using the 29-base AE-labeled G tail HPA probe and the single-stranded synthetic 84-base G tail.
  • the signal intensity increased linearly as the increase in oligonucleotide dosage in the range of 0.05 fmol to 10 fmol.
  • the present invention provides a method of measuring the length of the sequence of the telomere single-stranded tail (G tail) specifically and rapidly at high sensitivity without tedious processing operation and denaturation and a kit for use therein.
  • the kit according to the present invention is useful as a test reagent for patients with various diseases relevant to cancer and aging, which are regarded as diseases associated with G tail loss. It is also useful for use in basic physiological research on diseases associated with aging, cancer, and telomere abnormality.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US12/067,710 2005-09-21 2006-09-21 Method for determination of the length of the g-tail sequence and kit for the method Abandoned US20090298062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-274523 2005-09-21
JP2005274523 2005-09-21
PCT/JP2006/318783 WO2007034897A1 (fr) 2005-09-21 2006-09-21 Procédé de détermination de la longueur de la séquence d'une queue g et kit pour le procédé

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/318783 A-371-Of-International WO2007034897A1 (fr) 2005-09-21 2006-09-21 Procédé de détermination de la longueur de la séquence d'une queue g et kit pour le procédé

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/361,511 Division US9932627B2 (en) 2005-09-21 2012-01-30 Method for determination of the length of the G-tail sequence and kit for the method

Publications (1)

Publication Number Publication Date
US20090298062A1 true US20090298062A1 (en) 2009-12-03

Family

ID=37888940

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/067,710 Abandoned US20090298062A1 (en) 2005-09-21 2006-09-21 Method for determination of the length of the g-tail sequence and kit for the method
US13/361,511 Active US9932627B2 (en) 2005-09-21 2012-01-30 Method for determination of the length of the G-tail sequence and kit for the method

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/361,511 Active US9932627B2 (en) 2005-09-21 2012-01-30 Method for determination of the length of the G-tail sequence and kit for the method

Country Status (4)

Country Link
US (2) US20090298062A1 (fr)
EP (1) EP1935989B1 (fr)
JP (2) JP5514401B2 (fr)
WO (1) WO2007034897A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136611A (zh) * 2012-02-27 2014-11-05 东丽株式会社 核酸的检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88562B (pt) 1987-09-21 1994-02-28 Ml Technology Ventures Metodo de ensaio de proteccao homogeneo para a deteccao de um analito
PT88665B (pt) 1987-10-05 1992-12-31 Ml Tecnology Ventures Lp Metodo para a marcacao com ester de acridinio e purificacao de sondas nucleotidicas
US6117634A (en) * 1997-03-05 2000-09-12 The Reagents Of The University Of Michigan Nucleic acid sequencing and mapping
JP2001095586A (ja) * 1999-09-30 2001-04-10 Toshinori Ide テロメアサイズの測定方法
US20030162291A1 (en) 2000-06-22 2003-08-28 Seigfried Hekimi Clk-2, cex-7 and coq-4 genes, and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136611A (zh) * 2012-02-27 2014-11-05 东丽株式会社 核酸的检测方法

Also Published As

Publication number Publication date
EP1935989A4 (fr) 2009-11-11
JPWO2007034897A1 (ja) 2009-03-26
JP5514401B2 (ja) 2014-06-04
EP1935989A1 (fr) 2008-06-25
US20120190022A1 (en) 2012-07-26
WO2007034897A1 (fr) 2007-03-29
US9932627B2 (en) 2018-04-03
EP1935989B1 (fr) 2012-09-12
JP2014050407A (ja) 2014-03-20

Similar Documents

Publication Publication Date Title
KR101378214B1 (ko) 검체 해석 방법 및 그것에 사용하는 분석 키트
Shuber et al. Efficient 12-mutation testing in the CFTR gene: a general model for complex mutation analysis
EP0281927B1 (fr) Procédé pour déterminer une sequence d'acide nucléique dans un échantillon
JPH09504699A (ja) 変異及び多型性の検出、増幅されたｄｎａサンプルの精製、及び対立遺伝子の同定のための、固定化ミスマッチ結合蛋白質の使用
JPH04502862A (ja) 核酸配列上の一個の塩基を迅速に検出および／または同定する方法とその応用
JPH05504477A (ja) 特定のヌクレオチド変異の決定のための方法および試薬
EP1358355A2 (fr) Nouvelle methode de determination du genotype
JP2000508539A (ja) Ｓｔｒ座位の多重増幅
KR20150028063A (ko) 리포터 및 소광자가 결합된 프로브를 이용한 액상형 어레이 및 이를 이용한 표적핵산 또는 돌연변이 검출방법
US9499866B2 (en) Compositions and methods for detecting single nucleotide polymorphisms
US20060199202A1 (en) Detection of allelic expression imbalance
EP0408918A1 (fr) Méthode de détection d'acide nucléique
JPH08510919A (ja) 耳毒性難聴の罹病性変異の検出方法
WO2013122319A1 (fr) Procédé de détection de gène cible ou mutation associée utilisant une réaction de ligase et réaction d'amplification d'enzyme de coupure
AU2005221178B2 (en) Artificial mutation controls for diagnostic testing
US9932627B2 (en) Method for determination of the length of the G-tail sequence and kit for the method
KR20010051353A (ko) 변동된 종결 분석에 의한 핵산 서열의 변형 검출 방법
CN114540479A (zh) 用于检测与耳聋相关的基因snp的组合物、试剂盒及检测方法
EP2843047B1 (fr) Procédé de détection d'acides nucléiques
JP2011004733A (ja) 複数検体中の標的核酸を検出するマイクロアレイ
Kølvraa et al. Application of fluorescence in situ hybridization techniques in clinical genetics: use of two alphoid repeat probes detecting the centromeres of chromosomes 13 and 21 or chromosomes 14 and 22, respectively
US20030077584A1 (en) Methods and compositons for bi-directional polymorphism detection
US20040146875A1 (en) Method of identifying differences between nucleic acid molecules
Yeh et al. Compositions and methods for detecting single nucleotide polymorphisms
JP4528889B1 (ja) 検体解析方法およびそこにおいて使用されるアッセイキット

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION